Literature DB >> 19733029

Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity.

Maura S Oliveira1, Gladys V B Prado, Silvia F Costa, Renato S Grinbaum, Anna S Levin.   

Abstract

We compared 41 patients who received colistimethate with 41 who received polymyxin B for the treatment of serious infections caused by carbapenem-resistant Acinetobacter spp. and found both polymyxins have similar efficacy and toxicity.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19733029     DOI： 10.1016/j.diagmicrobio.2009.07.018

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  20 in total

1.  Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods.

Authors:  Brian C Nelson; Daniel P Eiras; Angela Gomez-Simmonds; Angela S Loo; Michael J Satlin; Stephen G Jenkins; Susan Whittier; David P Calfee; E Yoko Furuya; Christine J Kubin
Journal:  Antimicrob Agents Chemother       Date:  2015-08-31       Impact factor: 5.191

2.  In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy.

Authors:  Kady Phe; Yuman Lee; Patrick M McDaneld; Nishant Prasad; Taijun Yin; Deborah A Figueroa; William L Musick; Jessica M Cottreau; Ming Hu; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

Review 3.  Colistin and polymyxin B: peas in a pod, or chalk and cheese?

Authors:  Roger L Nation; Tony Velkov; Jian Li
Journal:  Clin Infect Dis       Date:  2014-04-03       Impact factor: 9.079

Review 4.  Polymyxin Resistance in Gram-negative Pathogens.

Authors:  Pavithra Srinivas; Kaitlyn Rivard
Journal:  Curr Infect Dis Rep       Date:  2017-09-11       Impact factor: 3.725

Review 5.  Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?

Authors:  Thien B Tran; Tony Velkov; Roger L Nation; Alan Forrest; Brian T Tsuji; Phillip J Bergen; Jian Li
Journal:  Int J Antimicrob Agents       Date:  2016-10-18       Impact factor: 5.283

6.  Colistin and polymyxin B for treatment of nosocomial infections in intensive care unit patients: pharmacoeconomic analysis.

Authors:  Júlia Coelho França Quintanilha; Natalia da Costa Duarte; Gustavo Rafaini Lloret; Marília Berlofa Visacri; Karen Prado Herzer Mattos; Desanka Dragosavac; Antonio Luis Eiras Falcão; Patricia Moriel
Journal:  Int J Clin Pharm       Date:  2018-12-15

7.  Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections.

Authors:  Yanina Dubrovskaya; Ting-Yi Chen; Marco R Scipione; Diana Esaian; Michael S Phillips; John Papadopoulos; Sapna A Mehta
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

8.  Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B.

Authors:  Maria Helena Rigatto; Maura S Oliveira; Lauro V Perdigão-Neto; Anna S Levin; Claudia M Carrilho; Marcos Toshiyuki Tanita; Felipe F Tuon; Douglas E Cardoso; Natane T Lopes; Diego R Falci; Alexandre P Zavascki
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

9.  Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin.

Authors:  Ryan L Crass; W Cliff Rutter; Donna R Burgess; Craig A Martin; David S Burgess
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

Review 10.  Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review.

Authors:  M C Gaspar; W Couet; J-C Olivier; A A C C Pais; J J S Sousa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-04-26       Impact factor: 3.267
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.